P192 Secukinumab provides rapid and sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 2-year results from the Phase 3 FUTURE 5 study

Abstract Background/Aims We report the 2-year effects of secukinumab on 78 tender joint count (TJC)/76 swollen joint count (SJC) scores in key subgroups of FUTURE 5: patients naive/with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFis), and patients with/without concomitant methotrexate (MTX) use. Methods 996 patients with active psoriatic arthritis, who received ≤3 prior TNFis and/or concomitant MTX, were randomised to secukinumab 300 or 150 mg with loading dose (LD), 150 mg without LD or placebo. Treatments were given at baseline, Weeks 1-4 and every 4 weeks thereafter. Placebo-treated patients were re-randomised to secukinumab 300/150 mg at Week 16 (non-responders) or 24 (responders). Secukinumab dose could be escalated from 150 to 300 mg from Week 60 and maintained thereafter. ACR20 response and changes in 78 TJC/76 SJC are reported over 2 years in TNFi-naive/IR and with/without concomitant MTX subgroups. Results The primary endpoint, ACR20 response at Week 16, is reported elsewhere. At Week 104, 78.1%, 81.8% and 80.8% of TNFi-naive patients achieved an ACR20 response versus 74.0%, 72.1% and 69.8% of TNFi-IR patients with secukinumab 300, 150 and 150 mg no LD, respectively. At the same timepoint, 76.5%, 80.2% and 78.3% of patients with concomitant MTX achieved an ACR20 response versus 77.6%, 78.6% and 77.6% of patients without concomitant MTX with secukinumab 300, 150 and 150 mg no LD, respectively. At Week 104, mean change from baseline in adjusted 78 TJC/76 SJC scores for TNFi-naive and TNFi-IR patients was -14.1/-8.6 and -19.0/-9.1 for secukinumab 300 mg, -15.7/-9.6 and -19.1/-12.2 for secukinumab 150 mg, and -17.7/-10.9 and -17.9/-9.9 for secukinumab 150 mg no LD, respectively (Table 1). At Week 104, mean change from baseline in adjusted 78 TJC/76 SJC scores for patients with and without concomitant MTX was -15.7/-8.5 and -15.1/-3.4 for secukinumab 300 mg, -16.4/-10.4 and -16.8/-10.1 for secukinumab 150 mg, and -17.0/-10.3 and -18.6/-11.1 for secukinumab 150 mg no LD, respectively. Conclusion Secukinumab provided rapid improvements in TJC and SJC at Week 16, which were sustained through Week 104, irrespective of TNFi history/concomitant MTX use. P192 Table 1:Selected baseline characteristics and 78 TJC and 76 SJC Results at Week 104Selected baseline characteristicsVariableSEC 300 mg (N = 222)SEC 150 mg (N = 220)SEC 150 mgno LD (N = 222)PBO (N = 332)Mean adjusted 78 TJC scoreTotal population19.821.221.821.2Mean adjusted